TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07241234: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria

Sponsor: Agios Pharmaceuticals, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$609,552

Rescue Site Savings

+$406,368

Unlock Full NCT07241234 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07241234 Rescue Dossier →